BTK and hematopoietic and lymphoid cell neoplasm: Zeng described 27 solid tumor cancer patients with increased total and nAb titers post-booster to WT and variants including Omicron in agreement with our results.5 Fendler researched 199 cancer patients and found a third BNT162b2 mRNA booster yielded 90% and 56% detectable Omicron NT in solid tumor and hematologic cancers, respectively.4 Those receiving anti-CD20 monoclonal antibodies and most receiving BTK inhibitors failed to have detectable Omicron NT.